Developer docs
API playgroundTry for free, no card

Search company profiles

New Wave Biotech

Full company profile

uuid0000ejk

Namestring
New Wave Biotech
Legal namestring
New Wave Biotech Ltd
Company typeenum
Private
Founded yearint
2022
Descriptiontext

New Wave Biotech is a UK-based AI software company founded in 2022 that provides simulation and optimization tools for downstream bioprocessing in biomanufacturing. Its core product, Bioprocess Foresight, is a hybrid AI platform that combines mechanistic scientific models with machine learning to simulate bioprocess scenarios, predict yield, unit economics, and environmental impact, and recommend optimal parameters across 18 downstream unit operations including centrifugation, filtration, chromatography, extraction, and drying. The platform achieves 6.5% prediction error from a single calibration run and 1.4–4X greater accuracy than industry average, validated at 350–700L pilot scale with CPI.

The platform is organized into four integrated modules: AI-Powered Process Simulation, Downstream Process Optimisation, Dynamic Techno-Economic Analysis (TEA), and an industry-first biotech-specific Life Cycle Assessment (LCA) tool aligned with ISO 14040/44 covering 15+ impact categories. New Wave Biotech generates revenue through enterprise SaaS subscriptions, custom optimization projects (multi-year engagements combining virtual and physical experimentation), and direct enterprise licensing. Pricing is quote-based and positioned at a fraction of traditional consultancy costs (TEA reports typically $20k–$40k, consultancy LCA studies $5k–$100k).

The company serves biotech developers (alternative proteins, cultivated meat, precision fermentation), food ingredients and biochemical companies, pharmaceutical and industrial biotechnology firms, and processing technology equipment companies. Named customers include Multus Biotechnology (growth media / cultivated meat, headline case study achieving 8.6X yield improvement, 55% cost reduction, 37.4% processing time reduction) and Liven Proteins (plant-based collagen). Strategic partnerships with CPI, Nurasa (Temasek-owned, Asia-Pacific), iMEAN (upstream strain design), EIT Food, Innovate UK, and Big Idea Ventures provide validation, geographic reach, and ecosystem access. The team of 1–10 operates fully remotely across the UK, Sweden, and Brazil, with registered headquarters in Manchester and operational base in London.

Short descriptiontext

New Wave Biotech builds Bioprocess Foresight, an AI-powered simulation platform that helps biomanufacturers optimize downstream processing, predict yields, and run integrated techno-economic and life cycle assessments. It serves biotech developers, food ingredients, and industrial biotech firms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioprocess simulation software, downstream process optimization, techno-economic analysis, biotech life cycle assessment, biomanufacturing AI platform
Industry2 codes
PRIMARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Bioprocess Simulation Software
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Platform Subscription
TypeSubscription Recurring
Description

SaaS-based access to Bioprocess Foresight platform including AI-powered simulation, downstream optimization, TEA, and LCA tools. Subscription model with pricing based on usage scope and feature access.

newwavebiotech.com
2Custom Optimization Projects
TypeProfessional Services
Description

Tailored work packages designing optimization programs for specific client needs including target production scale, quality requirements, and known process challenges. Includes iterative cycles of virtual experimentation and targeted physical testing with ongoing collaboration.

newwavebiotech.com
3Enterprise Licensing
TypeSubscription Recurring
Description

Direct licensing of platform capabilities to enterprise customers for internal use. Enables corporates to leverage historical experimental data to power future R&D and processing technology companies to accelerate sales and R&D.

newwavebiotech.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details2 tiers
1Enterprise SaaS Platform Access
ModelSubscriptionBilling cadenceAnnual
Notes

Full platform access including AI simulation, DSP optimization, TEA, and LCA capabilities. Pricing varies by organization size, usage scope, and feature requirements. Quote-based sales process.

newwavebiotech.com
2Custom Optimization Engagement
ModelOtherBilling cadenceMulti-year contract
Notes

Project-based pricing for tailored work packages. Multus engagement achieved 55% cost reduction with only 8 datasets over 12 months. Pricing reflects scope of optimization cycles and project duration.

newwavebiotech.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Bioprocess Foresight
Description

AI-powered downstream process optimisation platform with integrated techno-economic analysis and life cycle assessment for biomanufacturers.

newwavebiotech.com
Core offering1 text field

New Wave Biotech develops and sells Bioprocess Foresight, an AI-powered bioprocess simulation platform that virtually tests thousands of downstream processing scenarios to predict yield, unit economics and sustainability impact. The platform combines hybrid AI (mechanistic modeling plus machine learning) with integrated techno-economic analysis and biotech-specific life cycle assessment, enabling biomanufacturers to cut R&D experiments by up to 92% and reach optimal processes faster.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 55% unit cost reduction
+6 more records
Product overview1 text field

New Wave Biotech offers a single AI-powered platform called Bioprocess Foresight, structured as a core simulation platform with multiple integrated modules. The platform combines hybrid AI modelling (mechanistic science plus machine learning) with integrated techno-economic analysis and life cycle assessment. The product portfolio consists of four primary modules: (1) AI-Powered Process Simulation — the core simulation engine for virtual scenario testing; (2) Downstream Process Optimisation — automated optimisation across 18 unit operations; (3) Techno-economic Analysis (TEA) — dynamic cost and economic modelling; and (4) Life Cycle Assessment (LCA) — biotech-specific environmental impact analysis. All four modules operate within the unified Bioprocess Foresight platform, sharing data and models so that each optimisation cycle automatically reflects process performance, economics, and sustainability simultaneously.

Product and service2 records
1Bioprocess Foresight Platform
CategoryBioprocess Simulation Software
Description

AI-powered bioprocess simulation platform that simulates thousands of downstream processing scenarios, predicting yield, unit economics, and sustainability impact of the full process. Combines hybrid AI (mechanistic models + machine learning) with integrated techno-economic analysis and life cycle assessment to enable biomanufacturers to run more targeted experiments and reach optimal processes faster with 92% fewer experiments. Sold to R&D teams, sustainability directors, and operations leaders at biotech, food ingredients, alternative protein and pharmaceutical companies.

2Custom Optimization Projects
CategoryProfessional Services
Description

Project-based professional service engagements where New Wave Biotech designs tailored optimization programs for specific client needs, including target production scale, quality requirements and known process challenges. Engagements combine iterative cycles of in-silico virtual experimentation with targeted physical testing in close collaboration with the client's R&D team.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Strategic partnership connecting iMEAN's upstream metabolic modeling and strain design capabilities with New Wave Biotech's downstream process optimization, TEA, and LCA. Joint proposition gives teams visibility from organism design through to purification, cost, and sustainability from day one. Addresses the gap where organism design decisions cascade into purification complexity. Available for food ingredients, industrial biotechnology, cosmetics, and pharmaceuticals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

Partnership to address lipid extraction challenges in industrial biotechnology. Combines CPI's downstream processing expertise with New Wave Biotech's hybrid AI-powered simulation platform to optimize solvent and non-solvent extraction methods. Project aims to enhance scalability, cost efficiency, and sustainability. Supported by Innovate UK grant under UKRI National Engineering Biology Programme. Validation achieved 6.5% prediction error and 1.4-4X accuracy vs industry average.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-14
Description

Commercial partnership with Temasek-owned sustainable food and nutrition company. Nurasa gains access to Bioprocess Foresight platform for their ecosystem of food-tech innovators. New Wave Biotech gains access to Nurasa's Asia-wide network, food-grade pilot facilities, application expertise, and regulatory/GTM partnerships. Helps move promising food-tech ingredients from R&D to market-ready products. Joint whitepaper on 'Lean Startup Meets Food Tech' published.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-12
Description

Innovate UK-backed partnership to scale cultivated meat production using AI bioprocess optimization. New Wave Biotech optimizes downstream processes for Multus's growth media products. Achieved 8.6X yield improvement, 55% cost reduction, 37.4% processing time reduction. Project funded through Innovate UK Engineering Biology grant. Both companies supported by Big Idea Ventures.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Culture Biosciences
TypeDirect peer
Description

Cloud bioreactor platform that runs fermentation experiments remotely for biotech customers, accelerating bioprocess development and scale-up. Directly comparable to New Wave Biotech's mission of replacing slow, expensive wet-lab experimentation with faster, more data-rich bioprocess decision-making.

TypeDirect peer
Description

Cloud-based lab automation platform that designs and runs biology experiments using DOE methodologies, enabling scientists to automate R&D workflows. Overlaps directly with New Wave's AI-powered bioprocess simulation and experiment optimization, serving the same biology R&D buyer.

TypeDirect peer
Description

Cloud R&D platform for biotech with ELN, LIMS, and workflow capabilities sold to biopharma R&D teams. Comparable in that both are SaaS infrastructure for biotech R&D decision-making, though Benchling focuses on data management rather than bioprocess simulation specifically.

TypeEmerging player
Description

AI/ML platform for protein engineering and biology design. Comparable as a generative AI company serving biotech R&D teams using ML to compress experimental timelines, though Cradle is focused upstream on protein design rather than downstream process optimization.

TypeBroad incumbent
Description

Established process simulation software vendor serving chemicals, petrochemicals, and increasingly biopharma. Comparable as the incumbent process-simulation layer New Wave Biotech is targeting specifically for bioprocesses, with overlapping techno-economic capabilities.

TypeBroad incumbent
Description

Large synthetic biology platform with internal bioprocess optimization capabilities and a code base (Ginkgo Enzyme Catalysis platform) that competes for similar synthetic biology customers. Comparable as a broader end-to-end synbio platform but with internal rather than externalized software tooling.

TypeBroad incumbent
Description

Major bioprocessing equipment and solutions provider increasingly bundling digital and data analytics capabilities (e.g., BIOSTAT, PAT software) with its bioreactors. Comparable as a bioprocess technology incumbent with the resources to expand into process simulation and optimization.

TypeBroad incumbent
Description

Global bioprocessing solutions provider (part of Danaher) with digital tools for process development and manufacturing. Comparable as a major bioprocess equipment and services player whose installed base and digital offerings overlap with New Wave's target customers.

TypeOthers
Description

Cloud-native data platform for life sciences R&D and manufacturing that aggregates scientific data into a unified lakehouse. Comparable as enabling biopharma R&D data infrastructure, though TetraScience focuses on the data layer while New Wave focuses on the modeling/simulation layer on top.

TypeEmerging player
Description

ML-driven drug discovery and development platform combining high-throughput biology with machine learning. Comparable as an AI/ML company applying data-driven methods to compress biology R&D cycles, though focused upstream on target/drug discovery rather than bioprocess.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

New Wave Biotech

Bioprocess Simulation Softwarenewwavebiotech.com

New Wave Biotech builds Bioprocess Foresight, an AI-powered simulation platform that helps biomanufacturers optimize downstream processing, predict yields, and run integrated techno-economic and life cycle assessments. It serves biotech developers, food ingredients, and industrial biotech firms.

What New Wave Biotech does

New Wave Biotech is a UK-based AI software company founded in 2022 that provides simulation and optimization tools for downstream bioprocessing in biomanufacturing. Its core product, Bioprocess Foresight, is a hybrid AI platform that combines mechanistic scientific models with machine learning to simulate bioprocess scenarios, predict yield, unit economics, and environmental impact, and recommend optimal parameters across 18 downstream unit operations including centrifugation, filtration, chromatography, extraction, and drying. The platform achieves 6.5% prediction error from a single calibration run and 1.4–4X greater accuracy than industry average, validated at 350–700L pilot scale with CPI.

The platform is organized into four integrated modules: AI-Powered Process Simulation, Downstream Process Optimisation, Dynamic Techno-Economic Analysis (TEA), and an industry-first biotech-specific Life Cycle Assessment (LCA) tool aligned with ISO 14040/44 covering 15+ impact categories. New Wave Biotech generates revenue through enterprise SaaS subscriptions, custom optimization projects (multi-year engagements combining virtual and physical experimentation), and direct enterprise licensing. Pricing is quote-based and positioned at a fraction of traditional consultancy costs (TEA reports typically $20k–$40k, consultancy LCA studies $5k–$100k).

The company serves biotech developers (alternative proteins, cultivated meat, precision fermentation), food ingredients and biochemical companies, pharmaceutical and industrial biotechnology firms, and processing technology equipment companies. Named customers include Multus Biotechnology (growth media / cultivated meat, headline case study achieving 8.6X yield improvement, 55% cost reduction, 37.4% processing time reduction) and Liven Proteins (plant-based collagen). Strategic partnerships with CPI, Nurasa (Temasek-owned, Asia-Pacific), iMEAN (upstream strain design), EIT Food, Innovate UK, and Big Idea Ventures provide validation, geographic reach, and ecosystem access. The team of 1–10 operates fully remotely across the UK, Sweden, and Brazil, with registered headquarters in Manchester and operational base in London.

New Wave Biotech firmographics

Firmographics
Name
New Wave Biotech
Legal name
New Wave Biotech Ltd
Website
https://newwavebiotech.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
New Wave Biotech builds Bioprocess Foresight, an AI-powered simulation platform that helps biomanufacturers optimize downstream processing, predict yields, and run integrated techno-economic and life cycle assessments. It serves biotech developers, food ingredients, and industrial biotech firms.
Ownership category
akta.pro rank

New Wave Biotech industry classification

Industry
Product category
Bioprocess Simulation Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Bioprocess simulation software
  • Downstream process optimization
  • Techno-economic analysis
  • Biotech life cycle assessment
  • Biomanufacturing AI platform

Where New Wave Biotech is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

New Wave Biotech business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Software Platform Subscription: SaaS-based access to Bioprocess Foresight platform including AI-powered simulation, downstream optimization, TEA, and LCA tools. Subscription model with pricing based on usage scope and feature access.
  2. Custom Optimization Projects: Tailored work packages designing optimization programs for specific client needs including target production scale, quality requirements, and known process challenges. Includes iterative cycles of virtual experimentation and targeted physical testing with ongoing collaboration.
  3. Enterprise Licensing: Direct licensing of platform capabilities to enterprise customers for internal use. Enables corporates to leverage historical experimental data to power future R&D and processing technology companies to accelerate sales and R&D.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise SaaS Platform Access
OtherMulti-year contractCustom Optimization Engagement

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

New Wave Biotech product offering

Product offering

Core offering

New Wave Biotech develops and sells Bioprocess Foresight, an AI-powered bioprocess simulation platform that virtually tests thousands of downstream processing scenarios to predict yield, unit economics and sustainability impact. The platform combines hybrid AI (mechanistic modeling plus machine learning) with integrated techno-economic analysis and biotech-specific life cycle assessment, enabling biomanufacturers to cut R&D experiments by up to 92% and reach optimal processes faster.

Product overview

New Wave Biotech offers a single AI-powered platform called Bioprocess Foresight, structured as a core simulation platform with multiple integrated modules. The platform combines hybrid AI modelling (mechanistic science plus machine learning) with integrated techno-economic analysis and life cycle assessment. The product portfolio consists of four primary modules: (1) AI-Powered Process Simulation — the core simulation engine for virtual scenario testing; (2) Downstream Process Optimisation — automated optimisation across 18 unit operations; (3) Techno-economic Analysis (TEA) — dynamic cost and economic modelling; and (4) Life Cycle Assessment (LCA) — biotech-specific environmental impact analysis. All four modules operate within the unified Bioprocess Foresight platform, sharing data and models so that each optimisation cycle automatically reflects process performance, economics, and sustainability simultaneously.

Differentiator

Problem solved

Functional benefit

Brands

  • Bioprocess Foresight: AI-powered downstream process optimisation platform with integrated techno-economic analysis and life cycle assessment for biomanufacturers.

Products and services

  • Bioprocess Foresight Platform AI-powered bioprocess simulation platform that simulates thousands of downstream processing scenarios, predicting yield, unit economics, and sustainability impact of the full process. Combines hybrid AI (mechanistic models + machine learning) with integrated techno-economic analysis and life cycle assessment to enable biomanufacturers to run more targeted experiments and reach optimal processes faster with 92% fewer experiments. Sold to R&D teams, sustainability directors, and operations leaders at biotech, food ingredients, alternative protein and pharmaceutical companies.
  • Custom Optimization Projects Project-based professional service engagements where New Wave Biotech designs tailored optimization programs for specific client needs, including target production scale, quality requirements and known process challenges. Engagements combine iterative cycles of in-silico virtual experimentation with targeted physical testing in close collaboration with the client's R&D team.

Quantifiable outcome

  • 55% unit cost reduction
  • +6 more outcomes

Companies that use New Wave Biotech

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

New Wave Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

New Wave Biotech partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • iMEANcoreStrategic or Co-development Partner · 17 March 2026Strategic partnership connecting iMEAN's upstream metabolic modeling and strain design capabilities with New Wave Biotech's downstream process optimization, TEA, and LCA. Joint proposition gives teams visibility from organism design through to purification, cost, and sustainability from day one. Addresses the gap where organism design decisions cascade into purification complexity. Available for food ingredients, industrial biotechnology, cosmetics, and pharmaceuticals.
  • CPI (Centre for Process Innovation)coreStrategic or Co-development Partner · 7 October 2025Partnership to address lipid extraction challenges in industrial biotechnology. Combines CPI's downstream processing expertise with New Wave Biotech's hybrid AI-powered simulation platform to optimize solvent and non-solvent extraction methods. Project aims to enhance scalability, cost efficiency, and sustainability. Supported by Innovate UK grant under UKRI National Engineering Biology Programme. Validation achieved 6.5% prediction error and 1.4-4X accuracy vs industry average.
  • NurasacoreStrategic or Co-development Partner · 14 January 2025Commercial partnership with Temasek-owned sustainable food and nutrition company. Nurasa gains access to Bioprocess Foresight platform for their ecosystem of food-tech innovators. New Wave Biotech gains access to Nurasa's Asia-wide network, food-grade pilot facilities, application expertise, and regulatory/GTM partnerships. Helps move promising food-tech ingredients from R&D to market-ready products. Joint whitepaper on 'Lean Startup Meets Food Tech' published.
  • Multus BiotechnologycoreStrategic or Co-development Partner · 12 December 2023Innovate UK-backed partnership to scale cultivated meat production using AI bioprocess optimization. New Wave Biotech optimizes downstream processes for Multus's growth media products. Achieved 8.6X yield improvement, 55% cost reduction, 37.4% processing time reduction. Project funded through Innovate UK Engineering Biology grant. Both companies supported by Big Idea Ventures.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

New Wave Biotech competitors and assessment

Company assessment

Direct peers

  • Culture Biosciences: Cloud bioreactor platform that runs fermentation experiments remotely for biotech customers, accelerating bioprocess development and scale-up. Directly comparable to New Wave Biotech's mission of replacing slow, expensive wet-lab experimentation with faster, more data-rich bioprocess decision-making.
  • Synthace: Cloud-based lab automation platform that designs and runs biology experiments using DOE methodologies, enabling scientists to automate R&D workflows. Overlaps directly with New Wave's AI-powered bioprocess simulation and experiment optimization, serving the same biology R&D buyer.
  • Benchling: Cloud R&D platform for biotech with ELN, LIMS, and workflow capabilities sold to biopharma R&D teams. Comparable in that both are SaaS infrastructure for biotech R&D decision-making, though Benchling focuses on data management rather than bioprocess simulation specifically.

Emerging players

  • Cradle: AI/ML platform for protein engineering and biology design. Comparable as a generative AI company serving biotech R&D teams using ML to compress experimental timelines, though Cradle is focused upstream on protein design rather than downstream process optimization.
  • Insitro: ML-driven drug discovery and development platform combining high-throughput biology with machine learning. Comparable as an AI/ML company applying data-driven methods to compress biology R&D cycles, though focused upstream on target/drug discovery rather than bioprocess.

Broad incumbents

  • Aspen Technology: Established process simulation software vendor serving chemicals, petrochemicals, and increasingly biopharma. Comparable as the incumbent process-simulation layer New Wave Biotech is targeting specifically for bioprocesses, with overlapping techno-economic capabilities.
  • Ginkgo Bioworks: Large synthetic biology platform with internal bioprocess optimization capabilities and a code base (Ginkgo Enzyme Catalysis platform) that competes for similar synthetic biology customers. Comparable as a broader end-to-end synbio platform but with internal rather than externalized software tooling.
  • Sartorius: Major bioprocessing equipment and solutions provider increasingly bundling digital and data analytics capabilities (e.g., BIOSTAT, PAT software) with its bioreactors. Comparable as a bioprocess technology incumbent with the resources to expand into process simulation and optimization.
  • Cytiva: Global bioprocessing solutions provider (part of Danaher) with digital tools for process development and manufacturing. Comparable as a major bioprocess equipment and services player whose installed base and digital offerings overlap with New Wave's target customers.

Others

  • TetraScience: Cloud-native data platform for life sciences R&D and manufacturing that aggregates scientific data into a unified lakehouse. Comparable as enabling biopharma R&D data infrastructure, though TetraScience focuses on the data layer while New Wave focuses on the modeling/simulation layer on top.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

New Wave Biotech social profiles

Digital presence

New Wave Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

New Wave Biotech leadership team

Management profile

Number of profiles

Profiles2 records

New Wave Biotech funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

New Wave Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New Wave Biotech

What does New Wave Biotech do?

New Wave Biotech develops and sells Bioprocess Foresight, an AI-powered bioprocess simulation platform that virtually tests thousands of downstream processing scenarios to predict yield, unit economics and sustainability impact. The platform combines hybrid AI (mechanistic modeling plus machine learning) with integrated techno-economic analysis and biotech-specific life cycle assessment, enabling biomanufacturers to cut R&D experiments by up to 92% and reach optimal processes faster.

Is New Wave Biotech a public or private company?

New Wave Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was New Wave Biotech founded?

New Wave Biotech was founded in 2022. It employs 1 to 10 people.

Where is New Wave Biotech based?

New Wave Biotech is headquartered in London, United Kingdom, in the Europe region.

How does New Wave Biotech make money?

Three revenue lines are on record. Software Platform Subscription is the primary driver. The others are custom Optimization Projects and enterprise Licensing.

Who are New Wave Biotech's main competitors?

Direct peers on record are Culture Biosciences, Synthace and Benchling. Emerging players are Cradle and Insitro. Broad incumbents are Aspen Technology, Ginkgo Bioworks, Sartorius and Cytiva. TetraScience is listed as an others.

Does New Wave Biotech have an API?

No public API is recorded for New Wave Biotech.

What industry is New Wave Biotech in?

New Wave Biotech's product category is Bioprocess Simulation Software. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GreenqueenFood Companies Using More AI to Scale Bioprocesses, But Expectation-Reality Gap RemainsThe article reports on food companies' increased use of AI in bioprocess development, with startups like MOA Foodtech and collaborations such as New Wave Biotech and iMEAN providing AI-driven solutions. Despite 76% of executives accelerating AI adoption, only 8% believe it fully meets expectations, hindered by data costs, expertise gaps, and trust issues. The article discusses potential benefits and risks of AI in food tech, including climate impact and operational efficiency.WorldbiomarketinsightsNew Wave Biotech and iMEAN launch AI solution for biomanufacturingNew Wave Biotech and iMEAN have launched a comprehensive bioprocess optimization platform aimed at improving efficiency in biomanufacturing. The partnership integrates upstream and downstream manufacturing processes, achieving significant results like 8.6x yield improvements and 92 percent fewer experiments in previous applications. This solution responds to growing demand for domestic biomanufacturing capacity, driven by regulatory initiatives in the EU, US, and China.WorldbiomarketinsightsNew Wave Biotech and Nurasa partner to scale food innovationNew Wave Biotech and Nurasa have launched a partnership to accelerate the commercialization of sustainable food technologies by combining AI bioprocess simulations with Nurasa's physical innovation infrastructure. The collaboration will use Nurasa's Bioprocess Foresight platform to virtually test thousands of production scenarios, potentially reducing physical experiments by 90% while providing visibility into cost, yield, and environmental impact. The partners aim to position Singapore as a regional launchpad for scaling food-tech and biomaterial innovations across Asia and Europe.AsiafoodjournalNew Wave Biotech partners with Nurasa to accelerate sustainable food and ingredient innovations to scaleNew Wave Biotech, a UK-based AI bioprocess simulation company, has entered a commercial partnership with Nurasa, a Singapore-based sustainable food and nutrition company owned by Temasek, to accelerate moving food-tech and ingredient innovations from R&D to market. The partnership gives companies in Nurasa's ecosystem access to New Wave Biotech's Bioprocess Foresight platform, which can reduce physical experiments by up to 90% and halve unit costs, while Nurasa provides Asia-wide network access, pilot facilities, and regulatory support. By linking digital modeling with real-world scale-up environments, the two companies aim to strengthen the commercial pathway for biomanufactured ingredients across Asia and Europe.ProteinproductiontechnologyNew Wave Biotech unveils first biotech-specific LCA to bring sustainability into early process designNew Wave Biotech launched the biomanufacturing sector's first Life Cycle Assessment solution built specifically for biotechnology processes, integrated directly into its AI-enabled simulation and optimization platform, enabling teams to quantify environmental impacts in real time while simultaneously evaluating cost and performance. The tool automates what traditionally required months of consultancy-led studies costing between US$5,000 and US$100,000, addressing a long-standing gap where sustainability assessments are disconnected from early-stage process development. An early adopter, Liven Proteins, has already used the platform to evaluate environmental impacts associated with fermentation-based collagen production.Scientific ComputingNew Wave Biotech brings Life Cycle Assessment (LCA) to biomanufacturingNew Wave Biotech has introduced a Life Cycle Assessment (LCA) tool for biomanufacturing, enabling instant assessment of environmental impacts and process optimization.vegconomistBiotech Manufacturers Gain Environmental Impact Insights with New LCA ToolNew Wave Biotech has launched a new Life Cycle Assessment tool tailored for the biotechnology sector, integrated directly into their AI-driven process simulation platform. The automated tool provides real-time environmental impact data—including climate change, energy consumption, and resource usage—at a fraction of the time and cost of traditional LCAs, which can take months and cost tens of thousands of dollars. Early adopter Liven Proteins is already using the platform to assess environmental impact in its fermentation-based collagen production, as biomanufacturers face increasing regulatory pressure under frameworks like the Corporate Sustainability Reporting Directive.LinkedIn#biotech #syntheticbiology #altprotein #sustainability #innovation #funding #ai #biomanufacturingNew Wave Biotech has secured €1.2 million in equity and grant funding from investors Innovate UK and EIT Food to expand its AI-powered bioprocess simulation technology. The capital will be used to grow the team and accelerate the commercialization of alternative protein solutions, aiming to address scaling challenges in synthetic biology.